NCT06894979 - Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline GliomaChildhood GlioblastomaChildhood Malignant Glioma

Interventions

DRUG

ATM Kinase Inhibitor AZD1390

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood and cerebrospinal fluid collection

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

RADIATION

Radiation Therapy

Undergo radiation therapy

OTHER

Survey Administration

Ancillary studies

Trial Locations (15)

15224

RECRUITING

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

RECRUITING

Children's National Medical Center, Washington D.C.

30329

RECRUITING

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

35233

RECRUITING

Children's Hospital of Alabama, Birmingham

38105

RECRUITING

Saint Jude Children's Research Hospital, Memphis

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

RECRUITING

Riley Hospital for Children, Indianapolis

48109

RECRUITING

C S Mott Children's Hospital, Ann Arbor

55455

RECRUITING

University of Minnesota/Masonic Cancer Center, Minneapolis

63110

RECRUITING

Washington University School of Medicine, St Louis

77030

RECRUITING

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

79415

RECRUITING

UMC Cancer Center / UMC Health System, Lubbock

80045

RECRUITING

Children's Hospital Colorado, Aurora

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

92868

RECRUITING

Children's Hospital of Orange County, Orange

All Listed Sponsors

lead

Children's Oncology Group

NETWORK